1. Pink Sheet
  2. >>R&D

US FDA Program Streamlining COVID-19 Treatment Development Still Working As Emergency Ends

 
• By Derrick Gingery

Any program changes would not occur until after a thorough assessment, the agency said.

COVID-19 treatment
Many of the types of potential COVID-19 treatments studied leveled after an early rise in interest. • Source: Shutterstock

US Food and Drug Administration officials will continue accelerating COVID-19 treatment development after the public health emergency ends, even as other operations transition away from a pandemic posture.

The FDA said the Coronavirus Treatment Acceleration Program (CTAP) remains active and that changes would be made only “after a thorough assessment of the existing needs and available product development...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

Australia Looks To Modernize Human Tissue Laws, Improving Access For Researchers

 
• By Eliza Slawther

Australia is reviewing its human tissue laws for the first time in almost 50 years, and is hoping to reduce barriers to access for scientific researchers, for instance by addressing issues with access to cell lines for developing drugs.

China NMPA Lays Out Regulatory Priorities At DIA

 
• By Xu Hu

At this year’s DIA China meeting, the national regulator updated its policy focus areas for this year, including clinical trial data protection and pilot projects to shorten IND approval times.

US FDA Cell-Gene Therapy Head Says Agency Has Revived Stalled Programs

 
• By Sarah Karlin-Smith

CBER's Nicole Verdun wants rare disease sponsors with stalled treatments to circle back because the FDA's evolved thinking on clinical trial designs may offer another opportunity for cast away products.